Sigrun Erkens-Schulze

Sigrun Erkens-Schulze

Auto-generated profile, based on publicly available information

Sigrun Erkens-Schulze

Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
SBStefan A.J. Buck
Stefan A.J. Buck
AHAnnelies Van Hemelryk
Annelies Van Hemelryk
CRCorrina de Ridder
Corrina de Ridder
DSDebra Stuurman
Debra Stuurman
SESigrun Erkens-Schulze
Sigrun Erkens-Schulze
Wytske Van WeerdenWytske Van Weerden
Wytske Van Weerden
Resistance to taxane chemotherapy is frequently observed in metastatic prostate cancer. The androgen receptor (AR) is a major driver of prostate cancer and a key regulator of the G1–S cell-cycle checkpoint, promoting cancer cell proliferation by irreversible passage to the S-phase. We hypothesized that AR signaling inhibitor (ARSi) darolutamide in combination with docetaxel could augment antitumor effect by impeding the proliferation of taxane-resistant cancer cells. We monitored cell viability in organoids, tumor volume, and PSA secretion in patient-derived xenografts (PDX) and analyzed cell cycle and signaling pathway alterations. Combination treatment increased antitumor effect in androgen-sensitive, AR-positive prostate cancer organoids and PDXs. Equally beneficial effects of darolutamide added to docetaxel were observed in a castration-resistant model, progressive on docetaxel, enzalutamide, and cabazitaxel. In vitro studies showed that docetaxel treatment with simultaneous darolutamide resulted in a reduction of cells entering the S-phase in contrast to only docetaxel. Molecular analysis in the prostate cancer cell line LNCaP revealed an upregulation of cyclin-dependent kinase inhibitor p21, supporting blockade of S-phase entry and cell proliferation. Our results provide a preclinical support for combining taxanes and darolutamide as a multimodal treatment strategy in patients with metastatic prostate cancer progressive on ARSi and taxane chemotherapy.

17 June 2026
Verified
Other
Open access
SBStefan A.J. Buck
Stefan A.J. Buck
AHAnnelies Van Hemelryk
Annelies Van Hemelryk
CRCorrina de Ridder
Corrina de Ridder
DSDebra Stuurman
Debra Stuurman
SESigrun Erkens-Schulze
Sigrun Erkens-Schulze
Wytske Van WeerdenWytske Van Weerden
Wytske Van Weerden
Combination of docetaxel and darolutamide in C4-2B4 and LNCaP. Dose-response curve with mean normalized viability (+/- SEM) of two (A-B) or three (C-D) separate experiments with technical triplicates. Curves were interpolated by non-linear regression analysis and used to determine absolute IC50 value.

17 June 2026
Verified
Other
Open access
PDF file
SBStefan A.J. Buck
Stefan A.J. Buck
AHAnnelies Van Hemelryk
Annelies Van Hemelryk
CRCorrina de Ridder
Corrina de Ridder
DSDebra Stuurman
Debra Stuurman
SESigrun Erkens-Schulze
Sigrun Erkens-Schulze
Wytske Van WeerdenWytske Van Weerden
Wytske Van Weerden
Combination of docetaxel and darolutamide in PC346C-Enzalutamide resistant cells. A: Dose-response curve with mean normalized viability (+/- SEM) of three separate experiments with technical sextuplicates. Curves were interpolated by non-linear regression analysis and used to determine absolute IC50 value.

17 June 2026
Verified
Other
Open access
SBStefan A.J. Buck
Stefan A.J. Buck
AHAnnelies Van Hemelryk
Annelies Van Hemelryk
CRCorrina de Ridder
Corrina de Ridder
DSDebra Stuurman
Debra Stuurman
SESigrun Erkens-Schulze
Sigrun Erkens-Schulze
Wytske Van WeerdenWytske Van Weerden
Wytske Van Weerden
Darolutamide and docetaxel pharmacokinetics in PC346C bearing mice, related to Figure 2A-C. A: Mean systemic darolutamide concentrations in PC346C bearing mice treated with darolutamide, with or without docetaxel (n=8 and n=9 per group, respectively) directly after oral darolutamide administration at treatment initiation (start), 2 weeks or 4 weeks after treatment initiation and at time of mouse sacrifice (end). B: Mean systemic docetaxel concentrations in PC346C bearing mice treated with docetaxel, with or without darolutamide (n=8 per group) directly after i.v. docetaxel administration.


1 June 2021 in European Urology
Verified
Journal Article
Closed access
AHAnnelies Van Hemelryk
Annelies Van Hemelryk
ITI. Tomljanovic
I. Tomljanovic
CRC.M.A. De Ridder
C.M.A. De Ridder
DSD. Stuurman
D. Stuurman
SES. Erkens-Schulze
S. Erkens-Schulze
Wytske Van WeerdenWytske Van Weerden
Wytske Van Weerden